Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.13
-0.0100-0.24%
Post-market: 4.140.0100+0.24%19:30 EDT
Volume:889.18K
Turnover:3.65M
Market Cap:129.23M
PE:-1
High:4.28
Open:4.23
Low:4.01
Close:4.14
52wk High:50.40
52wk Low:4.01
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.15
T/O Rate:4.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.59
PE(LYR):-1.45

Loading ...

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

GlobeNewswire
·
Sep 01

Ceryvyn Therapeutics Plans New Options Issue to Bolster Capital

TIPRANKS
·
Sep 01

Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares

TIPRANKS
·
Sep 01

Major Insider Move at CAMP4 Therapeutics Raises Investor Eyebrows

TIPRANKS
·
Sep 01

Rakovina Therapeutics Narrows Q2 Loss as AI-Focused Cancer Pipeline Advances

TIPRANKS
·
Sep 01

AN2 Therapeutics presents clinical data supporting development of Epetraborole

TIPRANKS
·
Sep 01

Rakovina Therapeutics Closes Upsized $1.99 Million Private Placement to Advance AI-Driven Cancer Pipeline

TIPRANKS
·
Sep 01

Tenax Therapeutics Cut to Neutral from Buy by Guggenheim

Dow Jones
·
Aug 31

Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway

TIPRANKS
·
Aug 31

Allogene Therapeutics Announces Participation in September Investor Conference

GlobeNewswire
·
Aug 31

Press Release: Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Dow Jones
·
Aug 31

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live
·
Aug 31

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

GlobeNewswire
·
Aug 31

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

GlobeNewswire
·
Aug 31

Kazia Therapeutics Unveils New Investor-Focused Website

TIPRANKS
·
Aug 31

Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program

TIPRANKS
·
Aug 31

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

GlobeNewswire
·
Aug 31

Guggenheim Downgrades Tenax Therapeutics to Neutral From Buy

MT Newswires Live
·
Aug 31

Crispr Therapeutics Price Target Maintained with a $82.00/Share by Needham

Dow Jones
·
Aug 31

Cutia Therapeutics Accelerates Commercial Push in China’s Dermatology Market

TIPRANKS
·
Aug 31